These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

255 related articles for article (PubMed ID: 8222652)

  • 1. Effects of a low-estrogen, desogestrel-containing oral contraceptive on lipid and carbohydrate metabolism.
    Godsland IF; Crook D; Worthington M; Proudler AJ; Felton C; Sidhu M; Stevenson JC
    Contraception; 1993 Sep; 48(3):217-27. PubMed ID: 8222652
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A comparative metabolic study of two low-estrogen-dose oral contraceptives containing desogestrel or gestodene progestins.
    Crook D; Godsland IF; Worthington M; Felton CV; Proudler AJ; Stevenson JC
    Am J Obstet Gynecol; 1993 Nov; 169(5):1183-9. PubMed ID: 8238183
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Relationships between blood pressure, oral contraceptive use and metabolic risk markers for cardiovascular disease.
    Godsland IF; Crook D; Devenport M; Wynn V
    Contraception; 1995 Sep; 52(3):143-9. PubMed ID: 7587185
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effects of different formulations of oral contraceptive agents on lipid and carbohydrate metabolism.
    Godsland IF; Crook D; Simpson R; Proudler T; Felton C; Lees B; Anyaoku V; Devenport M; Wynn V
    N Engl J Med; 1990 Nov; 323(20):1375-81. PubMed ID: 2146499
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical and metabolic study of a new pill containing 20 mcg ethinylestradiol plus 0.150 mg desogestrel.
    Fioretti P; Fruzzetti F; Navalesi R; Ricci C; Miccoli R; Cerri M; Orlandi MC; Melis GB
    Contraception; 1987 Mar; 35(3):229-43. PubMed ID: 2956055
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hemostatic and metabolic effects of lowering the ethinyl-estradiol dose from 30 mcg to 20 mcg in oral contraceptives containing desogestrel.
    Basdevant A; Conard J; Pelissier C; Guyene TT; Lapousterle C; Mayer M; Guy-Grand B; Degrelle H
    Contraception; 1993 Sep; 48(3):193-204. PubMed ID: 8222650
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oral contraceptive tablets containing 20 and 30 micrograms of ethinyl estradiol with 150 micrograms desogestrel. Their influence on lipids, lipoproteins, sex hormone binding globulin and testosterone.
    Akerlund M; Almström E; Högstedt S; Nabrink M
    Acta Obstet Gynecol Scand; 1994 Feb; 73(2):136-43. PubMed ID: 8116352
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A cross-over study of three oral contraceptives containing ethinyloestradiol and either desogestrel or levonorgestrel.
    Song S; Chen JK; Yang PJ; He ML; Li LM; Fan BC; Rekers H; Fotherby K
    Contraception; 1992 Jun; 45(6):523-32. PubMed ID: 1535580
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A two-year clinical study of the effects of two triphasic oral contraceptives on plasma lipids.
    Kakis G; Powell M; Marshall A; Woutersz TB; Steiner G
    Int J Fertil Menopausal Stud; 1994; 39(5):283-91. PubMed ID: 7820162
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative metabolic effects of three types of combined oral contraceptive pills in Chinese women.
    Prasad RN; Liew D; Ratnam SS
    Contraception; 1989 Jan; 39(1):21-35. PubMed ID: 2521321
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of estrogen/progestin potency on lipid/lipoprotein cholesterol.
    Wahl P; Walden C; Knopp R; Hoover J; Wallace R; Heiss G; Rifkind B
    N Engl J Med; 1983 Apr; 308(15):862-7. PubMed ID: 6572785
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of levonorgestrel and desogestrel in low-dose oral contraceptive combinations on serum lipids, apolipoproteins A-I and B and glycosylated proteins.
    Bergink EW; Kloosterboer HJ; Lund L; Nummi S
    Contraception; 1984 Jul; 30(1):61-72. PubMed ID: 6236951
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum lipid and lipoprotein changes induced by new oral contraceptives containing ethinylestradiol plus levonorgestrel or desogestrel.
    Gaspard UJ; Buret J; Gillain D; Romus MA; Lambotte R
    Contraception; 1985 Apr; 31(4):395-408. PubMed ID: 3159546
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Insulin resistance, secretion, and metabolism in users of oral contraceptives.
    Godsland IF; Walton C; Felton C; Proudler A; Patel A; Wynn V
    J Clin Endocrinol Metab; 1992 Jan; 74(1):64-70. PubMed ID: 1530790
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fasting plasma lipids, lipoproteins and apolipoproteins in Nigerian women using combined oral and progestin-only injectable contraceptives.
    Oyelola OO
    Contraception; 1993 May; 47(5):445-54. PubMed ID: 8513671
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative effects of monophasic desogestrel plus ethinyloestradiol and triphasic levonorgestrel plus ethinyloestradiol on lipid metabolism.
    Kloosterboer HJ; van Wayjen RG; van den Ende A
    Contraception; 1986 Aug; 34(2):135-44. PubMed ID: 2946552
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A comparative study of the effects of a monophasic and a triphasic oral contraceptive containing ethinyl estradiol and levonorgestrel on lipid and lipoprotein metabolism.
    Loke DF; Ng CS; Samsioe G; Holck S; Ratnam SS
    Contraception; 1990 Nov; 42(5):535-54. PubMed ID: 2125546
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of three low-dose oral contraceptive formulations on lipid metabolism.
    Bertolini S; Elicio N; Cordera R; Gapitanio GL; Montagna G; Croce S; Saturnino M; Balestreri R; De Cecco L
    Acta Obstet Gynecol Scand; 1987; 66(4):327-32. PubMed ID: 2962417
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Time-dependent alterations in lipid metabolism during treatment with low-dose oral contraceptives.
    Kuhl H; März W; Jung-Hoffmann C; Heidt F; Gross W
    Am J Obstet Gynecol; 1990 Jul; 163(1 Pt 2):363-9. PubMed ID: 2142576
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oral contraceptives and coronary heart disease: modulation of glucose tolerance and plasma lipid risk factors by progestins.
    Crook D; Godsland IF; Wynn V
    Am J Obstet Gynecol; 1988 Jun; 158(6 Pt 2):1612-20. PubMed ID: 3287933
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.